Experts say the tool, described in the June Nature Biotechnology, could help rein in the skyrocketing
costs of vaccine development.
Not exact matches
«However, the promising results
of this trial lay the foundations for the
development of a more
cost - effective, clinically - practical
vaccine technology that could deliver similar outcomes for patients.
GSK, which has invested more than $ 300 million in RTS, S to date, has pledged to keep the price as low as possible — just manufacturing
costs plus a small return to be reinvested in
development of second - generation malaria
vaccines or
vaccines against other neglected tropical diseases.
Bill and Melinda Gates Foundation awards MIT, University College London, and University
of Kansas $ 17.6 M for
development and production
of low -
cost vaccines.